KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations · FRAMINGHAM · MA
High confidence (85%)
Updated Oct 14, 2026, 12:02 AM
What is happening
Derived by rule set status-rules-2026.09.7
The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.
Latest material event: KalVista Pharmaceuticals, Inc. deregistered its securities (Jun 22, 2026)
Timeline
Every material event, newest first. History is never overwritten.
KalVista Pharmaceuticals, Inc. deregistered its securities
Jun 22, 2026
Registration withdrawn
- SEC EDGAR — “15-12G 1 ef20076530_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36830 KalVista Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 200 Crossing Boulevard Framingham, Massachusetts 01702 (857) 999-0075 (Address, including zip code, and telephone number, including area code, of…”
KalVista Pharmaceuticals, Inc. received a delisting notice from its exchange
Jun 11, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 and Item 5.01 are incorporated herein by reference. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosures under Item 1.01 are incorporated by herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note and Item 2.01 are incorporated herein by reference. On June 10, 2026, the Company notified the Nasdaq Stock Market LLC ( Nasdaq ) of the anticipated consummation of the Merger and reques…”
KalVista Pharmaceuticals, Inc. was delisted from its exchange
Jun 11, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001348911 KalVista Pharmaceuticals, Inc. 001-36830 Building 227 Tetricus Science Park Porton Down Salisbury, Wiltshire X0 UNITED KINGDOM SP4 0JQ 44 (0) 1980 753002 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-06-11”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- SEC CIK
- 0001348911
- Website
- —
- —
- Headquarters
- FRAMINGHAM, MA
- Also known as
- Carbylan Biosurgery, Inc, Carbylan Therapeutics, Inc.
- Legal entities
- KalVista Pharmaceuticals, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
KalVista Pharmaceuticals, Inc. — Pharmaceutical Preparations (SIC 2834) — FRAMINGHAM, MA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
15-12G 1 ef20076530_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36830 KalVista Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 200 Crossing Boulevard Framingham, Massachusetts 01702 (857) 999-0075 (Address, including zip code, and telephone number, including area code, of…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0001348911 KalVista Pharmaceuticals, Inc. 001-36830 Building 227 Tetricus Science Park Porton Down Salisbury, Wiltshire X0 UNITED KINGDOM SP4 0JQ 44 (0) 1980 753002 Common Stock 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-06-11
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 and Item 5.01 are incorporated herein by reference. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosures under Item 1.01 are incorporated by herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note and Item 2.01 are incorporated herein by reference. On June 10, 2026, the Company notified the Nasdaq Stock Market LLC ( Nasdaq ) of the anticipated consummation of the Merger and reques…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Sep 18, 2026, 01:30 AM
The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:46 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:12 AM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:12 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.